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 Introduction 
 Epidemiology of Alcohol Use Disorders in Opioid 
Dependence 
 Substance use disorders, including opioid depen-
dence, are defined by a cluster of somatic, psychological 
and behavioral symptoms. The worldwide prevalence of 
opioid use disorders is 0.4%, and about 12 million people 
use heroin worldwide  [1–3] . In Europe, about 1.35 mil-
lion individuals are affected  [1] . In the USA, the 12-month 
prevalence of drug abuse was recently estimated at 5.7% 
 [4] . Approximately 3.7 million individuals have used her-
oin at least once in their lives and 750,000–1,000,000 in-
dividuals are currently heroin dependent  [5] . 
 Opioid dependence is frequently associated with poly-
substance use and alcohol use disorders (AUD), and the 
latter cause multiple health and social problems  [3, 6–8] . 
This paper presents a comprehensive review of the exist-
ing literature on the prevalence and treatment of AUD in 
opioid dependence.
 Neurobiological Interrelationships between Alcohol 
and Opioid Use 
 Opioid and alcohol abuse and dependence show some 
close neurobiological interrelations. In brief, like other 
drugs of abuse both alcohol and opioids induce dopamine 
 Key Words 
 Alcohol · Alcoholism opioids · Opioid dependence · 
Maintenance therapy · Buprenorphine · Methadone 
 Abstract 
 Maintenance therapy with methadone or buprenorphine is 
an established and first-line treatment for opioid depen-
dence. Clinical studies indicate that about a third of patients 
in opioid maintenance therapy show increased alcohol con-
sumption and alcohol use disorders. Comorbid alcohol use 
disorders have been identified as a risk factor for clinical out-
come and can cause poor physical and mental health, in-
cluding liver disorders, noncompliance, social deterioration 
and increased mortality risk. The effects of opioid mainte-
nance therapy on alcohol consumption are controversial 
and no clear pattern has emerged. Most studies have not 
found a change in alcohol use after initiation of maintenance 
therapy. Methadone and buprenorphine appear to carry lit-
tle risk of liver toxicity, but further research on this topic is 
required. Recent data indicate that brief intervention strate-
gies may help reduce alcohol intake, but the existing evi-
dence is still limited. This review discusses further clinical im-
plications of alcohol use disorders in opioid dependence. 
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release in the ventral tegmental area and nucleus accum-
bens; the psychotropic effects of alcohol are in part medi-
ated via the opioid-endorphin system  [9–11] . Alcohol 
stimulates the release of beta-endorphin, enkephalins and 
dynorphin  [12–16] , and opioids stimulate alcohol intake 
via the paraventricular nucleus  [17] . Opioid receptor 
blockade decreases alcohol intake  [18–21] . Studies have 
provided broad evidence for a significant role of the opi-
oid system in mediating the reinforcing effects of alcohol 
and the associated dopamine release in the mesolimbic 
brain area  [15, 19, 22–26] . 
 Clinically, both alcohol and opioids are ‘downers’, i.e. 
they have a strong sedative effect and cause respiratory 
depression. Many studies have addressed the possible 
role of mu-opioid receptor polymorphisms in mediating 
the genetic risk for alcohol or substance use in general. 
The OPRM1 variant was found in a recent meta-analysis 
to have a modest protective effect on the risk for sub-
stance use in comparison to the 1799971 (A118G ASN40/
ASP40) G allele  [27] . This gene variant may modulate 
treatment response to the opioid antagonist naltrexone, 
which is used for alcohol treatment  [28] . ASP40-ASN40 
heterozygotes may respond better than ASP40 homozy-
gotes to naltrexone  [29] .
 Search Methods 
 A systematic literature search was performed in the 
Medline and Pubmed databases to identify clinical and 
epidemiogical studies on a possible association between 
opioid dependence and AUD. The search was not limited 
to certain years or languages. The indexing terms were 
‘methadone AND alcoholism’ (402 citations) and ‘bu-
prenorphine AND alcoholism’ (48 citations). In addition, 
the terms ‘opioids and alcohol’ were screened. Papers fo-
cusing on epidemiology, diagnosis, therapy or other clin-
ical issues were considered to be of special relevance.
 Diagnosis of AUD in Opioid Dependence 
 A patient may present with the typical clinical picture 
of being intoxicated or generally drinking too much, i.e. 
alcohol breath, increased body sway, red skin, CNS symp-
toms such as irritability, anxiety and restlessness, or, in 
more severe cases, withdrawal symptoms such as sweat-
ing, tremor, tachycardia or increased blood pressure ( ta-
ble  1 ). A breathalyzer may help to verify alcohol con-
sumption. Increased liver enzymes can also help to iden-
tify patients, but they have low specificity because many 
patients have hepatitis or other liver disorders. Increased 
mean corpuscular volume (MCV) or carbohydrate-defi-
cient transferrin values are other relevant biomarkers for 
alcoholism  [30–32] . More recently, direct alcohol metab-
olites, especially ethyl glucuronide, was reported to be 
useful for measuring alcohol consumption in patients on 
opioid maintenance therapy  [33–35] . Also, the 5HTOL/
HIAA ratio in urine was used to detect alcoholism in 
methadone maintenance patients  [36] .
 The standardized Addiction Severity Index (ASI) in-
terview or its European variant, the EuropASI  [37] , can 
be used in clinical studies to identify alcohol problems. 
The Alcohol Use Disorder Identification Test (AUDIT, 
10 items)  [38, 39] is recommended by the WHO for clin-
ical use and to screen patients, and is frequently used in 
clinical studies (see below). 
 Prevalence of AUD in Opioid Dependence 
 Prevalence estimates for AUD in opioid dependence 
vary. Approximately one third of the patients in metha-
done treatment are assumed to have alcohol problems 
 [40–42] . More recent data by and large confirm these find-
ings. An Irish study estimated the prevalence of problem 
 Table 1.  Detection of alcoholism in opioid dependence
Detection of AUD in 
opioid-maintained patients
Clinical correlates of 








Intoxication Blood alcohol 
 concentration
Noncompliance, 






 increase, other clinical 
symptoms
Poor health, younger age, 
victimization, lack of 




AUDIT, ASI, others Higher dosages of opioid 
maintenance drug 
 requested by non-alcohol-
abusing clients [7]
Psychosocial Deterioration Perceived stress, low 
 quality of life [64]
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alcohol use among patients attending primary care for 
methadone treatment at 35%  [43] . Data from the  British 
National Treatment Outcome Research Study (NTORS) 
suggest that almost half of the patients in residential pro-
grams drink alcohol and just over a third of those in com-
munity programs drink above the recommended levels 
 [6] . A Swiss 2-year longitudinal study found occasional 
alcohol abuse in 38–47% of methadone patients and daily 
abuse in 20–24%  [44] . A recent  Australian study reported 
that 41% of opioid substitution clients were ‘AUDIT pos-
itive’, indicating excessive alcohol use  [45] , but only half 
of them believed they drank too much. 
 In a large German study  [46] in 1,685 heroin users and 
patients on opioid maintenance treatment (with metha-
done or codeine), 28% of participants consumed more 
than 40 g alcohol/day. The average alcohol consumption 
was significantly higher in heroin users than in metha-
done-treated patients. Predictors of alcohol use were male 
sex, daily cannabis and benzodiazepine consumption, and 
longer duration of drug use. Meta-analyses of US clinical 
trials found AUD in 38 and 45% of patients seeking treat-
ment for opioid or stimulant use, respectively  [47, 48] .
 Clinical Correlates of AUD in Opioid Dependence 
 AUD are associated with an increased risk of fatal over-
dose  [49]  (see below), hepatotoxicity (especially in hepati-
tis-positive individuals)  [50] , interactions with methadone 
 [51, 52] and negative clinical outcome  [53, 54] . Hepatitis 
infections are very common in opioid users  [55] . Preva-
lence estimates of hepatitis C range from 64 to 100% in 
many cohorts  [56–62] . Chronic alcohol intake is an impor-
tant risk factor for progression to hepatic cirrhosis  [50] . 
 Alcohol dependence and AUD are usually considered 
to be risk factors for compliance and predictors for a neg-
ative treatment outcome, although this has not been re-
ported in all studies  [63] . According to recent data, sub-
stance use, including alcohol-related problems, may be 
attributed to perceived stress  [64] . Stress management 
may therefore be a suitable approach to minimize the risk 
of alcohol intake.
 Most patients with alcohol abuse show noncompli-
ance and nonadherence to treatment  [65] . Inadequate 
opioid dosage during maintenance therapy may explain 
alcohol or other drug use in some patients. Ottomanelli 
 [7] found that non-alcohol-abusing clients request higher 
doses of opioids. 
 Sebanjo et al.  [42] evaluated the effects of excessive al-
cohol consumption on the health-related quality of life in 
patients receiving methadone treatment and found sig-
nificant impairments in various domains, including so-
cial functioning. 
 Genetic variables have hardly been studied to date. 
Wang et al.  [66] reported that a kappa-opioid receptor 1 
gene polymorphism is associated with alcohol use, among 
other things. 
 AUD and Mortality in Opioid-Dependent Patients 
 There is broad consensus that opioid-dependent pa-
tients have a substantial risk of premature death, mostly 
associated with fatal overdose or polysubstance intoxica-
tions  [67] . Long-term studies in opioid-dependent indi-
viduals indicate a low abstinence and high mortality rate 
 [67–70] . The all-cause mortality rate was estimated at 
2.09 per 100 person-years  [71] . Problem drug users were 
found by the European Monitoring Centre for Drugs and 
Drug Addiction  [1] to have a 10- to 20-fold higher mor-
tality risk than their peers. Maintenance treatment sig-
nificantly reduces mortality rates compared with untreat-
ed heroin dependence  [71] .
 AUD are associated with an increased risk of fatal 
overdose in opioid dependence  [72] and numerous stud-
ies have identified alcohol abuse or dependence as a risk 
factor for mortality in opioid-dependent patients  [73] . 
Degenhardt et al.  [74] recently published a comprehen-
sive study on causes of death in the years 1995–2005 in a 
large Australian cohort (n = 43,789) of opioid-dependent 
people. Of the 3,685 deaths, the majority (52%) were drug 
related and were mostly accidental opioid deaths; 3% 
were alcohol related and 7% were liver related (3% chron-
ic liver disease and 3% viral hepatitis). The standard mor-
tality ratio for the most common causes of death for alco-
hol-related disorders was 5.4%. Because both heavy and 
dependent alcohol use have been described in older opi-
oid-dependent people  [75] , screening for and treatment 
of hazardous alcohol use is recommended for this group 
 [74] . Another recent large (n = 68,066) retrospective co-
hort study also found a high mortality rate: drug- or alco-
hol-induced deaths accounted for 23% of the cases  [76] . 
 Brief Update on the Efficacy of Maintenance 
Treatment  
 A number of psychosocial approaches and therapies 
with the goal of abstinence from opioids have proven ef-
ficacy in opioid dependence, but overall abstinence rates 
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are rather low and rarely exceed 20%  [77] . Maintenance 
treatment with full or partial opioid agonists reduces opi-
oid consumption, criminal behavior and psychosocial 
and medical morbidity, including rates of HIV and hepa-
titis B virus infections, as indicated by many studies and 
meta-analyses  [78–84] . The efficacy of buprenorphine 
and its combination with naloxone in reducing substance 
use and improving social and clinical functioning in opi-
oid-dependent individuals has been demonstrated by nu-
merous studies  [84–87] and both methadone and bu-
prenorphine are recommended as effective, first-line 
medications in the treatment of opioid dependence by 
relevant treatment guidelines  [5, 88–90] and reviews  [78, 
80, 82, 83, 85, 91] . 
 Role of Opioid Maintenance Therapy in Alcohol 
Consumption 
 The interaction of opioid dependence, maintenance 
therapy and alcohol consumption is complex ( table 2 ). 
Addressing opioid dependence adequately by increasing 
the dose of maintenance treatment does not automati-
cally decrease alcohol consumption  [92, 93] . For example, 
short-term methadone maintenance therapy was report-
ed to decrease alcohol consumption and long-term treat-
ment to increase it as indicated by the data reviewed by 
Caputo et al.  [94] . Hser et al.  [95] reported that alcohol 
consumption increases whenever narcotic use decreases, 
and Anglin et al.  [96] also claimed that alcohol and hero-
in use are inversely related. Caputo et al.  [94] reported a 
significant reduction in daily alcohol intake in metha-
done-treated, nonalcoholic, opioid-dependent patients 
compared to nonmethadone-dependent clients. In an 
18-month longitudinal cohort study on exposure to treat-
ment for heroin addiction, Schifano et al.  [97] found that 
heroin, benzodiazepine and polydrug abuse decreased 
over time, but alcohol (and cannabis) use did not. Fish-
man et al.  [98] reported on a female patient with an ad-
diction to prescription opioids and comorbid depression 
and alcohol dependence who benefited from treatment 
with buprenorphine. 
 In some European countries heroin is used to treat 
opioid dependence. A secondary analysis of a random-
ized German study comparing heroin treatment with 
methadone treatment  [99] found a significant reduction 
in carbohydrate-deficient transferrin values in both 
groups, but a reduction in the ASI alcohol subscore only 
in the heroin group. Interestingly, this result was dis-
cussed with respect to setting effects: daily dispensing of 
heroin may have prevented this group from consuming 
more alcohol. A reduction in the ASI alcohol subscore 
was also reported in a large German naturalistic follow-
up study of 1,694 patients in opioid maintenance treat-
ment for 6–7 years; the study also found a higher rate of 
‘critical’ alcohol consumption in methadone patients 
(36–50%) than in buprenorphine patients (24–27%) over 
time  [100] .
 Some studies suggest that opioid maintenance therapy 
suppresses alcohol intake in heroin addicts with alcohol 
 Table 2.  AUD in opioid dependence
Study Methods Key findings
The effect of methadone 
 maintenance treatment on 
alcohol consumption: 
a systematic review [8]
Systematic review of 15 studies Alcohol use:
Increased in 3 studies
Decreased in 3 studies
Did not change in 9 studies
Opioid maintenance therapy 
 suppresses alcohol intake in heroin 
addicts with alcohol dependence 
[101]
Open randomized 12-month study, MET 
(80, 120, 160 and 200 mg) or BUP (8, 16, 
24 and 32 mg) (n = 218)
Both treatments suppressed opioid and alcohol 
consumption (ASI scores)
Highest BUP dose better than highest MET dose 
on alcohol craving and intake
Effects of heroin-assisted treatment 
on alcohol consumption [99]
Secondary analysis of self-reported 
 alcohol consumption, CDT, ASI scores 
Randomized trial: heroin vs. MET
Both groups: significant reduction of alcohol use 
and CDT
Heroin group: reduction of ASI score
Effect of daily frequency of heroin dispensing 
(setting effect)?
 BUP = Buproprione; CDT = carbohydrate-deficient transferrin; MET = methadone.
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dependence. In a 12-month open randomized study, the 
effects of methadone (80, 120, 160 and 200 mg) and bu-
prenorphine (8, 16, 24 and 32 mg) on opioid and alcohol 
consumption (as measured by ASI scores) were assessed 
in 218 patients  [101] . Both treatments decreased opioid 
and alcohol consumption, but the only statistically sig-
nificant finding was that the highest buprenorphine dose 
suppressed alcohol craving and intake more than the 
highest methadone dose.
 Srivastava et al.  [8] performed a systematic review of 
15 studies on the effects of methadone treatment on alco-
hol consumption. Three studies indicated an increase in 
alcohol use during treatment and 3 indicated a decrease; 
9 studies did not report any change. Apparently there is 
no clear pattern concerning the effects of opioid mainte-
nance therapy on alcohol consumption.
 The US Substance Abuse and Mental Health Services 
Administration (SAMHSA) concluded the following in 
their clinical guidelines for the use of buprenorphine in 
the treatment of opioid addiction  [102] : ‘Pharmacother-
apy with buprenorphine for opioid addiction will not 
necessarily have a beneficial effect on an individual’s use 
of other drugs. It is essential that patients be referred to 
treatment of addiction to other types of drugs when indi-
cated. In addition, care must be exercised in the prescrib-
ing of buprenorphine for patients who abuse alcohol… 
because of the documented potential for fatal interac-
tions.’ This may be true for all drugs used for opioid 
maintenance treatment.
 Treatment of AUD in Opioid-Dependent Patients 
 The issue of AUD in opioid-dependent patients has 
been widely neglected. A 1-year follow-up study found 
improvements in alcohol consumption in a minority of 
patients only  [6] . Because many patients underestimate 
the risks associated with their alcohol consumption, alco-
hol use should be regularly assessed and brief alcohol in-
terventions performed when necessary  [45] .
 Only a few systematic studies have been published on 
AUD in opioid dependence  [103, 104] . When preparing 
their systematic Cochrane review on this topic, Klimas et 
al.  [105, 106] identified 4 studies with 594 participants. 
The studies measured 6 different psychosocial interven-
tions grouped into 4 comparisons: cognitive-behavioral 
coping skills training versus 12-step facilitation (n = 41) 
 [107] , brief intervention versus treatment as usual (n = 
110)  [108] , hepatitis health promotion versus motiva-
tional interviewing (n = 256)  [65] , and brief motivational 
intervention versus an assessment-only group (n = 187) 
 [109] . The authors were not able to perform a meta-anal-
ysis of all the studies because of clinical and methodolog-
ical differences between them. Most of the comparisons 
were not statistically significant, except for decreased al-
cohol use at 3 and 9 months with the control intervention 
in the studyby Feldman et al.  [108] . Also, at 6 months 
participants receiving brief motivational intervention 
were significantly more likely than the control group to 
have reduced their alcohol use by 7 or more days in the 
past 30 days  [109] . Similar to previous reviews  [103, 104] , 
the Cochrane review was unable to recommend using or 
ceasing psychosocial interventions for alcohol use prob-
lems in illicit drug users: ‘Given the high rates of co-oc-
currence of alcohol and drug problems, integration of al-
cohol- and drug-orientated interventions appears a logi-
cal action, but in light of this review remains without an 
evidence base’  [105] .
 The same group is currently conducting a study to de-
termine the feasibility of a complex intervention for prob-
lem alcohol use among problem drug users  [110] . A new 
and interesting study has been performed on this topic: 
Darker et al.  [111] studied the effectiveness of brief inter-
ventions to reduce hazardous and harmful alcohol con-
sumption in opiate-dependent methadone-maintained 
patients and excluded alcohol-dependent patients. The 
study assessed the change in scores on the Alcohol Use 
Disorders Identification Test (AUDIT-C) from baseline 
to the 3-month follow-up in 160 patients (15 were lost to 
follow-up). This implementation study found a clear re-
duction in alcohol consumption after treatment. Brief in-
terventions are frequently used in alcohol treatment 
 [112] , but not in treatment for addiction to illicit drugs.
 So-called anti-craving drugs such as the opioid antag-
onists naltrexone and nalmefene  [28, 113] and the puta-
tive glutamate modulator acamprosate  [114] may help to 
reduce alcohol consumption. The first two substances 
precipitate opioid withdrawal and are contraindicated in 
opioid-dependent patients, while acamprosate has not 
been tested in opioid users. The anticraving drug acam-
prosate has no contraindication in opioid dependence 
and no pharmacological interactions with opioids.
 The overall evidence for disulfiram as an effective 
medication in alcoholism is limited  [115, 116] and basi-
cally restricted to supervised treatment settings. Since 
opioid maintenance therapy may be considered as such a 
supervised setting, disulfiram may fit in here. Disulfiram 
was also studied as a possible medication for the treat-
ment of cocaine dependence in methadone-stabilized pa-
tients  [117] and positive results were reported in patients 
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maintained with buprenorphine  [118] , but disulfiram 
may also work in those with current alcohol use disorder 
 [107] . Unlike cocaine and possibly methadone, disulfi-
ram was not found to prolong the QTc interval  [119] .
 Hepatotoxicity in Opioid Maintenance Therapy 
 Hepatotoxicity must be considered when addressing 
AUD in opioid dependence. While methadone has been 
considered to be safe, clinical reports of liver injury in pa-
tients with hepatitis have raised concerns about the hepa-
totoxicity of buprenorphine and the buprenorphine/nal-
oxone combination  [120–126] . Hervè et al.  [127] report-
ed on 7 cases of acute cytolytic hepatitis due to 
buprenorphine. Five of 7 patients presented with acute 
icteric hepatitis without abdominal pain or fever or evi-
dence for liver failure; after reexposure some of the pa-
tients remained on a lower dose without further evidence 
of liver injury.
 More systematic studies found little evidence for bu-
prenorphine hepatotoxicity. Bogenschutz et al.  [128] 
studied 152 patients randomized to 2 weeks’ detoxifica-
tion with buprenorphine-naloxone or 12 weeks’ treat-
ment with buprenorphine-naloxone and obtained at least 
one set of transaminase measurements for 111 patients. 
At least one elevated aspartate aminotransferase value 
was found in 8 of the 60 buprenorphine/naloxone pa-
tients and 12 of the 51 detoxification patients. Hepatitis 
C status was significantly associated with transaminase 
abnormalities. Taken together, this exploratory study 
found no evidence for hepatotoxicity of buprenorphine.
 Saxon et al.  [129] performed a controlled study of 
1,269 opioid-dependent, treatment-seeking patients ran-
domized to either buprenorphine or methadone and fol-
lowed them for 32 weeks. A total of 731 participants met 
‘evaluable’ criteria, defined as completing 24 weeks of 
medication and providing at least 4 blood samples. 
Changes in transaminase levels did not differ by medica-
tion condition. The study found no evidence that bu-
prenorphine is associated with liver injury. A recent phase 
IV study also found no evidence for liver toxicity associ-
ated with buprenorphine  [31] . Data from a large study 
comparing short- and long-term effects of buprenor-
phine on liver function indicate that hepatitis C serocon-
version was strongly associated with ALT elevations 
 [130] .
 Methadone, but not buprenorphine, was found to 
have some rare cardiotoxic effects, including causing tor-
sades de pointes  [90] . The possibility of such side effects 
must be kept in mind when treating alcohol-dependent 
patients with possible cardiomyopathy. ECG controls are 
recommended. 
 Conclusions 
 The current data indicate that AUD are a significant 
problem in about a third of the patients in opioid main-
tenance therapy and have a significant impact on morbid-
ity and mortality. According to most studies, opioid 
maintenance therapy does not change alcohol consump-
tion, at least not in the majority of cases, but dose adjust-
ments may help to reduce the risk of substance use, in-
cluding alcohol. A simple diagnostic approach such as the 
use of a breathalyzer may be useful to detect affected pa-
tients. More research is needed on psychosocial strategies 
for use in patients with alcohol abuse. It is already difficult 
to define effective psychosocial interventions for the 
treatment of opioid use  [131, 132] , and therefore even 
more difficult to suggest evidence-based treatments for 
comorbid alcoholic patients. Brief interventions and 
treatment modifications, such as more regular visits or a 
more intense approach without prolonged periods at 
home, may be helpful. In more severe cases, selective (al-
cohol) detoxification may be considered. 
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